Compare Oracle Corporation (ORCL) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oracle Corporation vs Repligen Corporation Common Stock — how do they compare? Oracle Corporation trades at $127.75 (market cap $395.76B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Oracle Corporation is far larger — about 35× Repligen Corporation Common Stock's market cap, and Oracle Corporation pays a 1.53% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oracle Corporation for 73 Days and Repligen Corporation Common Stock for 0 Days on average.
| ORCL | RGEN | |
|---|---|---|
Market Cap | $395.76B | $11.31B |
Volume | 45,051,114 | 1,216,919 |
Sector | Technology | Health |
52-Week High | $313.00 | $194.57 |
52-Week Low | $114.99 | $102.87 |
Typical Hold Time | 73 Days | 0 Days |
Enterprise Value | $519.57B | $11.20B |
Dividend Yield | 1.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oracle (ORCL) trades at $143.22, up 4.24% today, but faces a bearish technical signal with the stock near support at $135. The company reported strong Q1 2026 earnings, beating EPS estimates with $2.11 versus $1.96 expected, and maintains robust profitability with a 26.36% net income margin. Revenue growth accelerated to $57.4 billion in 2025, up from $53.0 billion in 2024, driven by AI cloud demand.
Outlook remains positive given analyst consensus price target of $236.52, implying significant upside, but risks include high debt levels and sensitivity to Fed policy. The stock's current valuation at a P/E of 22.45 appears reasonable relative to earnings growth, though investor sentiment is cautious amid recent layoffs and market volatility.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
